DAFTAR PUSTAKA
1. Calmy A, Balestre E, Bonnet F, Boulle A, Sprinz E, Wood R, dkk. Mean CD4 cell count changes in patiensts failing a first-line antiretroviral therapy in resources-limited settings. BMC Infectious Diseaseas. 2012; 12( 47); 1-9. 2. World Health Organization. HIV/AIDS prevention, treatment and care in
health sector 2009. h.30-59.
3. Carmody, Alavi S, Ahmadi F, Farhadi M. Correlation between total lymphocyte count, hemoglobin, hematocrit and CD4 count in HIV/AID Patients. Acta Medica Iranica. 2009 ;47 (1) : 1-4.
4. Paoli M, Hung, Mills E, Gronningsaeter. The ARV roll out and disability grant : a South African dillemma ? Journal of the International AIDS Society. 2012; 15 : 6.
5. Macias E, Steven, Cosco D, Nguyen M, Rio C, Lennox J. Predictors of succes with highly active antiretroviral therapy in an antiretroviral-naïve urban population. AIDS Research and Human Retroviruses. 2010; 26 (2) : 133-137. 6. Hogg, Oxenius A, Price D, Hersberger M, Schlaefer E, Weber R, Weber M,
dkk. HIV-spesific cellular immune response is inversely correlated with disease progression as defined by decline of CD4 + T cells in relation to HIV RNA load. JID. 2004; 189 : 1199-208.
7. Hofman, Chan R. Biomedical strategies for human immunodeficiency virus (HIV) prevention ? A new paradigm. Ann Acad Med Siangapore. 2012; 41 : 595-601.
8. Mermin, Jong M, Hulsebosch H, Lange J. Clinical, virological and immunological features of primary HIV-Infection. Genitourin Med. 1991; 67 . 367-373.
9. Yasin M N. Analisis respon terapi antiretroviral pada pasien HIV/AIDS (Tesis). Yogyakarta : Universitas Gajah Mada Yogyakarta; 2001.
10.Lawn S, Myer L, Bekker L, Wood R. CD4 Cell count recovery among HIV-Infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-saharan African. BMC Infectious Diseaseas. 2006, 6: 59; 1-8.
11.Hirsh H, Kaufman 6, Sendi P. Battegay M. Immune Reconstitution in HIV-Infected Patients. Clinical Infectious Diseases. 2004; 38 : 1159-66.
12.Simon V, Ho D H, Karim Q A. HIV/AIDS epidemiology, pathogenesis, prevention and treatment. Lancet. 2006 ; 368 :(95): 489-504.
13.Makoae L N, Portillo C J, Uys L R, Diamini PS, Greff M, Chirwa M. The impact of taking or not taking ARVs on HIV stigma as reported by persons living with HIV infection in five African countries. AIDS Care. 2009; 21 (11) : 1357-1362.
14.Dwi Murtiastutik. AIDS. editor Jusuf Barakbah, Hans Lumintang, Sumarko Martodiharjo Buku Ajar Infeksi Menular Seksual. Airlangga University Press 2008 h:211-214.
15.Sabin, Caroline A, Philips, Andrew. Should HIV therapy be started at a CD4 cell count above 350 cells in asymptomatic HIV-1 infected patienst ? current Opinion in infectious Diseases. 2009; 22 (2): 191-197.
16.Grossman 2, Schellersheim MM, Souca A E, Victorino R M, Paul W E. CD 4 + T-cell depletion in HIV infection : Are We Closer to understanding the cause ? 2004 ;8 (4): 319-321.
17.Alimonthi J 8, Ball TB, Fowke K R. Mechanism of CD4 + T lymphocyte cell death in human immunodeficiency virus infection and AIDS. Journal of General virology. 2003; 84:1649-1661.
18.World Health Organization. Antiretroviral therapy for HIV in adults and adolescents recomendations for a public health approach 2010. h:69-76
19.World Health Organization. Laboratory guidelines for enumerating CD4 T lymphocytes 2007. h: 71-79
20.Kemenkes RI. Pedoman nasional tatalaksana klinis infeksi HIV dan terapi antiretroviral pada orang dewasa 2011.
21.World Health Organization. Rapid advice antiretroviral therapy for HIV infection in adults and adolescents 2009. h:76-81.
22.Admou Q, Elharti E, Qumail H, Add ebbous A, Amine M, Zahlane K, dkk. Clinical and immunological status of a newly diagnosed HIV positive population, in Marrakech, Morocco.JID. 2010 : 10 (4) I 325-329.
23.Calarota S A, Foli A, Maserati R, Baldanti F, Paolucci S, Young M, dkk. HIV-I-specific T cell precursors with high proliferative capacity correlate with low viremia and high CD4 counts in untreated individuals. J Immunol. 2008; 180 (9) ; 5907-5915.
24. Schaecker T W, Bosch R J, Bennett K, Pollard R, Robbins 6 K, Collier AC, dkk. Measurement of naive CD 4 cells reliably predicts potential for immune reconstitution in HIV. J Acquir Immune Defic Syndr. 2012 ; 54 (1) ; 59-62. 25.Gill C J, Griffith J L, Jacobson D, Skinner S, Gorbach S L, Wilson 1 B.
Relationship of HIV viral loads, CD 4 counts, HAART, use to health-related quality of life. JAIDS. 2002 ; 30 (2) ; 485-492.
26.Moore D M, Hogg R S, Yip B, Craib K, Wood E, Montaner JSG. CD4 Percentage is an. Independent predictor of survival in patients starting antiretroviral therapy with absolute CD 4 cell counts between 200 and 350 cells/ul. HIV Medicine. 2006; 7 : 282-388.
27.Longford S E, Ananworanich J, Cooper D A. Preditors of disease progression in HIV infection : areview. AIDS Research and therapy. 2007 ; 11 (4) ; 1-14. 28.Vanegas N T, Zapata W, Rugeles M T. Genetic and immunological factors
involved in natural resistance to HIV-infection. The open virology Journal. 2011; 5:35-43.
29.Fox J, Scriba T J, Robinson N, Weber J N, Philips R E, Fidler S. Human immunodeficiency virus (HIV) – specific T helper responses fail to predict CD4+ + cell decline following short course treatment at primary HIV-1 infection. Clinical and Experimental Immunology. 2008;152; 532-537.
30.Huang K H, Loutfy M R, Tsoukas CM, Bernard N F. Immune Correlates of CD 4 decline in HIV – Infected Patients Experiencing virologic failure before undergoing treatment interruption. BMC Infectious Diseases. 2008 : 8 (59). 31.Hoffman J, Griensven J, Colebunders R, Mc Kellar Mehri. Role of the CD4
court in HIV management. HIV ther. 2010 ; 4 (1) : 27-39.
32.Thomson M A, Aberg J-A, Cahn P, Montaner J S G, Rizzardini G, Telenti A. Antirertoviral treatment of adults HIV infection. JAMA. 2010 ; 304 (3) ; 321-357.
33.Prakash SK. Analogy of CD 4 cells, CD & cells and CD 4/CD 8 ratio in human immunodeficiency virus – 1 (HIV-1) infected Individuals treated with phytochemical therapy. I J APBC. 2012 ; 1(1): 161-167.
34.Scott. V, Zweigenthal V, Jennings K. Between HIV diagnosis and Initiation of antiretroviral therapy : assessing the effectiveness of care for people living with HIV in the public primary care service in Cape Town, south Africa. Tropical Medicine and International Health. 2011 : 16 (11) ; 1384-1391.
35.Kumara Samy N, Patel Atul, Pujari Sanjay. Antiretroviral therapy in Indian setting. When & what to start with, when & what to switch to ? Indian J Med Res. 2011: 134; 787-800.
36.Mandala J, Torpey K, Kansonde P, Kataso M, Dirks R, Suzuki C, dkk. Prevention of mother-to child transmission of HIV in Zambia : implementing efficacious ARV regimens in primary health centers. BMC Public health 2009 : 9 (3) ; 1-9.
37.Zhang M, Han X X, Cui W G, Jai M H, Meng X D, Xing A H. The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-I drug resistance mutation. Jpn. J- Iinfect Dis. 2008 : 61 ; 361-365.
38.Lanca A M, Collares J K, Ferreira J L, Lima D M, Brigido L F, Rodriques R, dkk. HIV-I Tropism and CD4 T lymphocyte recovery in a prospective cohort of patients initiating HAART in Ribeirao Preto. Brazil. Mem Inst Oswaldo Cruz. 2012 : 107 (1) ; 96-101.
39.Holstad MM, Dilorio C, Mc Carty F. Adherence, sexual risk and viral load in HIV-infected women prescribed antiretroviral therapy. AIDS patient care and STD. 2011 ; 25 (7) ; 431-437.
40.Dahlan S. Besar sampel dan cara pengambilan sampel. Edisi ke-3. Edisi 3. Penerbit Salemba Medika Jakarta 2009. h:72.
41.Akinbami A., Dosunmu A., Adediran A., Ajibola S. CD4 count pattern and demographic distribution of treatment-naive HIV patients in Lagos, Nigeria.AIDS Research and treatment. 2012 : 10;1-6.
